Peptide · Fact sheet
Pramlintide
Also known as Symlin · pramlintide acetate
Symlin received FDA approval for selected insulin-treated diabetes populations, but FDA lists its U.S. presentations as discontinued. Pramlintide is not approved as a stand-alone obesity medicine.
What is Pramlintide?
Pramlintide is a manufactured analog of amylin, a peptide hormone normally released with insulin after eating.
Amylin signaling affects stomach emptying, glucagon release, satiety, and blood glucose, which also made the pathway important in obesity-drug research.
Benefits & claims
It is the established clinical proof that amylin biology can be used therapeutically.
Weight changes in diabetes and older obesity trials helped motivate longer-acting amylin analogs such as cagrilintide, but the molecules and evidence are not interchangeable.
What the evidence supports
- Controlled diabetes trials showed improved glycemic outcomes when pramlintide was added in the labeled setting.
- Older obesity trials found weight-loss signals, but pramlintide did not become a stand-alone FDA-approved obesity medicine.
Research areas
- Glucose control with mealtime insulin
- Satiety and food intake
- Obesity and weight outcomes
- Obesity treatment outside the approved diabetes context
- Amylin-based combination medicines
Dosage & frequency
Historical product label informationThe historical Symlin label describes separate mealtime regimens for type 1 and type 2 diabetes. FDA product records list the branded products as discontinued.
Symlin: type 1 diabetes: historical label
Adults with type 1 diabetes using mealtime insulin
- Amount
- Start 15 mcg; labeled increments 30, 45 and 60 mcg as tolerated
- Frequency
- Immediately before major meals
- Route studied or labeled
- Subcutaneous
Requires prescriber-directed mealtime insulin adjustment and glucose monitoring. Historical labeling; branded FDA product records are discontinued.
Symlin: type 2 diabetes: historical label
Adults with type 2 diabetes using mealtime insulin
- Amount
- Start 60 mcg; increase to 120 mcg as tolerated
- Frequency
- Immediately before major meals
- Route studied or labeled
- Subcutaneous
Severe hypoglycemia risk; not standalone treatment. Historical labeling; branded FDA product records are discontinued.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Pramlintide and the investigational long-acting amylin analog cagrilintide have different schedules.
Interactions & precautions
- Concurrent mealtime insulin creates severe hypoglycemia risk and requires prescriber-directed insulin adjustment; oral drug absorption can also be delayed.
What is still unresolved
- The approved regimen does not establish standalone obesity treatment.
Side effects & risks
- The label carries a boxed warning for severe hypoglycemia when used with mealtime insulin, especially in type 1 diabetes.
- Nausea and other gastrointestinal effects are common.
- Its approved use requires clinical management that cannot be generalized to consumer weight-loss use.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Strong human evidence for approved usesRandomized trials support the scoped diabetes indication. Obesity research without insulin-treated diabetes is older and does not create a current stand-alone weight-management approval.
Studies
Controlled evidence for glycemic and weight outcomes in insulin-treated type 2 diabetes.
Older exploratory obesity study that does not establish an approved stand-alone use.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Appetite: reported experiences
Feeling fuller, harder insulin management
A commenter who had used Symlin described substantially better fullness, while finding insulin management more difficult.
Amount, frequency, route and duration could not be confirmed for this account.
The summary concerns the author's own experience only, not their claims about other users. Glucose outcomes and insulin exposure were not verified.
Read the original accountLess appetite but severe nausea
A different commenter described recurring nausea and reduced appetite, with post-meal glucose rises seeming delayed rather than eliminated.
Amount, frequency, route and duration could not be confirmed for this account.
This does not establish a glucose-control mechanism or quantify risk. Concurrent insulin and clinical records were not available.
Read the original accountEarly weight loss, diminishing practical benefit
Another commenter reported less appetite, weight loss and lower insulin requirements over several weeks, but later felt the benefit was less worthwhile.
Reported use in this account
- Product
- Symlin
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- A few months
Other exposures described: Insulin
The account's explanation of tolerance was not clinically confirmed, and weight and insulin changes were self-reported.
Read the original accountWeight: reported experiences
Early weight loss, diminishing practical benefit
Another commenter reported less appetite, weight loss and lower insulin requirements over several weeks, but later felt the benefit was less worthwhile.
Reported use in this account
- Product
- Symlin
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- A few months
Other exposures described: Insulin
The account's explanation of tolerance was not clinically confirmed, and weight and insulin changes were self-reported.
Read the original accountDigestion: reported experiences
Less appetite but severe nausea
A different commenter described recurring nausea and reduced appetite, with post-meal glucose rises seeming delayed rather than eliminated.
Amount, frequency, route and duration could not be confirmed for this account.
This does not establish a glucose-control mechanism or quantify risk. Concurrent insulin and clinical records were not available.
Read the original accountGlucose: reported experiences
Feeling fuller, harder insulin management
A commenter who had used Symlin described substantially better fullness, while finding insulin management more difficult.
Amount, frequency, route and duration could not be confirmed for this account.
The summary concerns the author's own experience only, not their claims about other users. Glucose outcomes and insulin exposure were not verified.
Read the original accountLess appetite but severe nausea
A different commenter described recurring nausea and reduced appetite, with post-meal glucose rises seeming delayed rather than eliminated.
Amount, frequency, route and duration could not be confirmed for this account.
This does not establish a glucose-control mechanism or quantify risk. Concurrent insulin and clinical records were not available.
Read the original accountEarly weight loss, diminishing practical benefit
Another commenter reported less appetite, weight loss and lower insulin requirements over several weeks, but later felt the benefit was less worthwhile.
Reported use in this account
- Product
- Symlin
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- A few months
Other exposures described: Insulin
The account's explanation of tolerance was not clinically confirmed, and weight and insulin changes were self-reported.
Read the original accountApproval status
FDA lists the U.S. Symlin presentations as discontinued. Its historical approval covered selected adults with type 1 or type 2 diabetes using mealtime insulin. Marketing discontinuation does not by itself establish an approval withdrawal or its reason.
U.S. Symlin products discontinued
Symlin received a product-specific diabetes approval. FDA now lists its U.S. presentations as discontinued; that marketing status does not by itself establish an approval withdrawal or the reason for discontinuation. Its obesity research did not create a stand-alone weight-loss approval.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether pramlintide has a useful modern obesity role compared with other agents
- Long-term outcomes for unapproved weight-management use
- How benefits and harms compare with longer-acting amylin analogs
- Which combination strategies, if any, will prove clinically superior
Summary
Symlin has a historical diabetes approval and discontinued U.S. marketing status. Its label and trials do not establish a stand-alone weight-loss approval.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA Drugs@FDA dataset: Symlin product status
All three listed Symlin products have discontinued marketing status; this does not establish approval withdrawal.
- fdaFDA prescribing information: Symlin
Approved population, boxed warning, adverse reactions, and clinical evidence.
- pubmedOne-year randomized pramlintide diabetes trial
Controlled evidence for glycemic and weight outcomes in insulin-treated type 2 diabetes.
- pubmedRandomized pramlintide obesity study
Older exploratory obesity study that does not establish an approved stand-alone use.